- Previous Close
27.05 - Open
27.35 - Bid --
- Ask --
- Day's Range
26.85 - 27.50 - 52 Week Range
25.95 - 45.48 - Volume
565,801 - Avg. Volume
1,100,728 - Market Cap (intraday)
16.086B - Beta (5Y Monthly) 1.56
- PE Ratio (TTM)
-- - EPS (TTM)
-1.87 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date Jun 16, 2023
- 1y Target Est
--
Microbio Co., Ltd. researches, develops, manufactures, and trades in biotech drugs and dietary supplements in Taiwan. The company provides MS-20 for fatigue and appetite loss associated with cancer chemotherapy; and Herbiron, which reveals symptoms of iron deficiency anemia. It also involved in the trading of organic foods; sale of beverages; provision of technology development, transfer, and consultation services; and publishing of magazine, as well as offers business consulting services. Microbio Co., Ltd. was incorporated in 2000 and is based in Taipei City, Taiwan.
www.twmicrobio.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 4128.TWO
View MorePerformance Overview: 4128.TWO
Trailing total returns as of 4/2/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4128.TWO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4128.TWO
View MoreValuation Measures
Market Cap
16.09B
Enterprise Value
14.13B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.34
Price/Book (mrq)
1.56
Enterprise Value/Revenue
8.20
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-63.89%
Return on Assets (ttm)
-1.97%
Return on Equity (ttm)
-10.08%
Revenue (ttm)
1.72B
Net Income Avi to Common (ttm)
-1.1B
Diluted EPS (ttm)
-1.87
Balance Sheet and Cash Flow
Total Cash (mrq)
2.55B
Total Debt/Equity (mrq)
5.19%
Levered Free Cash Flow (ttm)
-231.35M